Repeated superselective intraarterial bevacizumab after blood brain barrier disruption for newly diagnosed glioblastoma: a phase I/II clinical trial.
Patel NV, Wong T, Fralin SR, Li M, McKeown A, Gruber D, D'Amico RS, Patsalides A, Tsiouris A, Stefanov DG, Flores O, Zlochower A, Filippi CG, Ortiz R, Langer DJ, Boockvar JA.
Patel NV, et al. Among authors: zlochower a.
J Neurooncol. 2021 Nov;155(2):117-124. doi: 10.1007/s11060-021-03851-2. Epub 2021 Oct 3.
J Neurooncol. 2021.
PMID: 34601657
Clinical Trial.